Just Published: Adjuvant pembrolizumab after resected stage III melanoma led to a 5-year recurrence-free survival of 55.4%, compared with 38.3% in patients treated with placebo. Read more in NEJM Evidence: https://eviden.cc/3x6Wg6l #ESMO22 | The New England Journal of Medicine

Current standard immunotherapy with medications such as keytruda, opdivo or yervoy results vary depending on many factors with a 24 month survival rate of 53% in melanoma, a better responding cancer, with occasional cures. These therapies are expensive, have side effects and still are lacking in results. We now have made a quantum leap in cancer treatment by adding ablation with vaccine adjuvants, completely blowing away the results of standard immunotherapy. https://williamscancerinstitute.com

#ad KEYTRUDA is a breakthrough immunotherapy. For women with high-risk early-stage triple-negative breast cancer (TNBC), KEYTRUDA could be part of the treatment plan before and after surgery. | El Vocero de Puerto Rico

Don't miss out on your chance to discover the latest FDA-approved combination of Keytruda and chemotherapy treatment. Learn From Experts On: ✔️ How Keytruda Works With Chemotherapy to Fight Mesothelioma ✔️What Patients Should Expect ✔️Clinical Trial Results and Patient Eligibility Factors Sign up now! https://buff.ly/3AR0hAS | The Mesothelioma Center